NASDAQ · PCRX
Pacira BioSciences, Inc.
$26.87 +$0.99 (+3.83%) 1D Market open
Session Pulse
Regular session
1
mentions on Wed
· 1 bullish
/ 0 bearish tags
No new SEC filings since Mon close
its sector ranked
5/11
this week
Full pulse →
Key Metrics
$1.02B
Market cap
198.19×
P/E · TTM
$734.86M
Revenue · TTM
$5.14M
Net income
EPS · TTM
$0.11
Dividend yield
—
Free cash flow
$132.71M
Beta · 1Y
0.30
EBITDA · TTM
$104.35M
Gross margin
—
Snapshot
Market cap$1.02B
Enterprise value$1.18B
Shares outstanding39.3M
52-wk range$18.80 – $27.64
Avg volume · 20D621.2K
Net cash
−$165.48M
Book value / share$14.05
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Pacira BioSciences, Inc.
IPO dateFeb 3, 2011
Employees829
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E198.19
P/S1.39
P/FCF7.67
EV/EBITDA11.34
EV/Sales1.61
Graham №$5.91
Profitability
Gross
—
Operating
1.8%
Net
0.7%
FCF
18.1%
ROE / ROIC
0.7% · 0.6%
Financial Health
Current ratio4.73
Quick ratio3.35
Debt / equity0.56
Debt / EBITDA
3.52
Net cash
−$165.48M
Working capital$406.17M
Cash Flow · TTM
Operating CF
$142.22M
Capex
−$9.51M
Free cash flow
$132.71M
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
6 / 9
Middling fundamentals · 6 of 9 signals passing
Altman Z-Score
1.9
Grey zone (1.81–2.99) · monitor
Graham Number vs Price
$5.91 vs $26.47
Trades 4.5× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings